AACR, Aging, Author Interviews, Cancer Research, Immunotherapy, Melanoma / 21.06.2018
Anti-PD1 Immunotherapy May Work Better in Older Melanoma Patients
MedicalResearch.com Interview with:
Ashani Weeraratna, Ph.D.
The Ira Brind professor and
Co-program leader of the Immunology, Microenvironment and Metastasis Program
The Wistar Institute
Member of Wistar’s Melanoma Research Center
Philadelphia
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: This study shows for the first time that older patients, especially those who have had prior MAPKi therapy fare better than younger patients when treated with anti-PD1. We found that tumors in younger patients and younger mice have higher levels of Tregulatory cells, the cells that regulate other immune cells. This is not true systemically, only within the tumor microenvironment.
We were surprised because we expected that, as with targeted therapy, older patients would have a poorer response to immunotherapy, given what we perceive as a poorer immune system in older patients. (more…)